Shares of Consort Medical plc (LON:CSRT) have earned a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 1,223.25 ($16.90).
Several equities research analysts have weighed in on CSRT shares. Numis Securities increased their price target on shares of Consort Medical from GBX 1,084 ($14.98) to GBX 1,144 ($15.81) and gave the company a “hold” rating in a research report on Wednesday, December 6th. N+1 Singer cut shares of Consort Medical to a “hold” rating in a research report on Tuesday, December 5th. Finally, Shore Capital reissued a “buy” rating on shares of Consort Medical in a research report on Tuesday, December 5th.
Shares of Consort Medical (LON:CSRT) opened at GBX 1,168 ($16.14) on Wednesday. Consort Medical has a 52 week low of GBX 976.09 ($13.49) and a 52 week high of GBX 1,230 ($16.99). The stock has a market capitalization of $572.66 and a price-to-earnings ratio of 2,920.00.
About Consort Medical
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.